Chemical Abstracts Service Registry Number: 66142-81-2
Formal Names: Alpha-Desmethyl DOB, 4-Bromo-2,5-Dimethoxyphenethylam-ine, 2-CB
Informal Names: BDMPEA, Bees, Bromo, Bromo-Mescaline, Erox, Eve, Herox, Honey Flip (with MDMA), Illusion, MFT, Nexus, Performax, Spectrum, Synergy, Venus, Zenith
Type: Hallucinogen. See page 25
Federal Schedule Listing: Schedule I (DEA no. 7392)
USA Availability: Illegal to possess
Pregnancy Category: None
Uses. This drug was created in the 1970s and is related to amphetamine, DOB, and mescaline.
Reports about alleged effects are plentiful, but 2C-B's Schedule I status means that most persons who think they are using 2C-B have acquired their product from an illegal drug dealer. Therefore, they do not really know what substance they are taking, and their accounts have no value. The drug's inventor Alexander Shulgin portrays the chemical as facilitating psychological insights that improve mental health, a quality that gained 2C-B a role in psychotherapy—both alone and in combination with MDMA, a combination that promoted empathy between users and other persons. Reports conflict about how much empathy is promoted by 2C-B itself. Intense emotions can occur, ranging from euphoria to fear. Physical senses can become more acute after the drug is administered. Research reported by a World Health Organization agency indicates 2C-B can make the senses of smell, taste, and touch more acute. This and other research describes 2C-B as a possible aphrodisiac. The substance is also a hallucinogen that can alter visual perceptions. The U.S. Drug Enforcement Administration made 2C-B a Schedule I substance in 1994.
Drawbacks. The drug is reported to have general stimulant actions that increase pulse rate and blood pressure and may be hazardous to epileptics and diabetics. Headache, chills, sweating, nausea, cramps, tremors, and reddened complexion are reported. Although sense of touch may be enhanced, sensitivity to pain may paradoxically be reduced, making a person less aware of injury—thereby increasing risk of harm. One authority warns against using the drug along with monoamine oxidase inhibitors (MAOIs), found in some antidepressants, lest the combination make a 2C-B dose too strong.
Abuse factors. Not enough scientific information to report.
Drug interactions. Not enough scientific information to report.
Cancer. Not enough scientific information to report.
Pregnancy. Not enough scientific information to report.
Additional scientific information may be found in:
De Boer, D., et al. "More Data about the New Psychoactive Drug 2C-B." Journal of
Analytical Toxicology 23 (1999): 227-28. Giroud, C., et al. "2C-B: A New Psychoactive Phenylethylamine Recently Discovered in Ecstasy Tablets Sold on the Swiss Black Market." Journal of Analytical Toxicology 22 (1998): 345-54. "Schedules of Controlled Substances; Placement of 4-Bromo-2,5-Dimethoxyphenethy-
lamine into Schedule I." Federal Register 55 (1996): 28718-719. Who Expert Committee on Drug Dependence. "Thirty-Second Report." WHO Technical Report Series 903 (2001): 6-8.
Was this article helpful?